534 results on '"Leebeek, Frank W.G."'
Search Results
2. Prediction of the chance of successful immune tolerance induction in persons with severe hemophilia A and inhibitors: a clinical prediction model
3. Variant mapping using mass spectrometry–based proteotyping as a diagnostic tool in von Willebrand disease
4. Psychometrics of patient-reported outcomes measurement information system in von Willebrand disease, inherited platelet function disorders, and rare bleeding disorders
5. Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS)
6. A multitrait genetic study of hemostatic factors and hemorrhagic transformation after stroke treatment
7. Predictive performance of pharmacokinetic-guided prophylactic dosing of factor concentrates in hemophilia A and B
8. The severe von Willebrand disease variant p.M771V leads to impaired anterograde trafficking of von Willebrand factor in patient-derived and base-edited endothelial colony-forming cells
9. Genetic variants, thrombocytopenia, and clinical phenotype of type 2B von Willebrand disease: a median 16-year follow-up study
10. Quantitative super-resolution imaging of platelet degranulation reveals differential release of von Willebrand factor and von Willebrand factor propeptide from alpha-granules
11. Poor correlation between biomarkers and MRI-detected joint damage in a cross-sectional study of persons with nonsevere hemophilia A (DYNAMO study)
12. A factor IX variant that functions independently of factor VIII mitigates the hemophilia A phenotype in patient plasma
13. Colorectal cancer screening in patients with inherited bleeding disorders: high cancer detection rate in hemophilia patients
14. von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS
15. In patients with hemophilia, a decreased thrombin generation profile is associated with a severe bleeding phenotype
16. Patients with moderate hemophilia A and B with a severe bleeding phenotype have an increased burden of disease
17. Desmopressin to prevent and treat bleeding in pregnant women with an inherited bleeding disorder: a systematic literature review
18. Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease
19. SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders
20. The bleeding phenotype in people with nonsevere hemophilia
21. Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results
22. Multi‐phenotype analyses of hemostatic traits with cardiovascular events reveal novel genetic associations
23. Joint status of patients with nonsevere hemophilia A
24. Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study
25. Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: A randomized controlled trial
26. COVID-19 vaccination in patients with immune thrombocytopenia
27. Von Willebrand disease type 2M: Correlation between genotype and phenotype
28. Surgical management of patients with von Willebrand disease: summary of 2 systematic reviews of the literature
29. Hepatitis C virus in hemophilia: Health‐related quality of life after successful treatment in the sixth Hemophilia in the Netherlands study
30. Validation of PROMIS Profile‐29 in adults with hemophilia in the Netherlands
31. Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972–2019
32. Treatment‐related risk factors for inhibitor development in non‐severe hemophilia A after 50 cumulative exposure days: A case‐control study
33. Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS
34. Quantitative 3D microscopy highlights altered von Willebrand factor α‐granule storage in patients with von Willebrand disease with distinct pathogenic mechanisms
35. Illustrated State‐of‐the‐Art Capsules of the ISTH 2021 Congress
36. Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial
37. Population pharmacokinetics of the von Willebrand factor–factor VIII interaction in patients with von Willebrand disease
38. Criteria for low von Willebrand factor diagnosis and risk score to predict future bleeding
39. Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001–2018
40. Major differences in clinical presentation, diagnosis and management of men and women with autosomal inherited bleeding disorders
41. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease
42. A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms
43. Peri-operative desmopressin combined with pharmacokinetic-guided factor VIII concentrate in non-severe haemophilia A patients
44. Psychometrics of patient-reported outcomes measurement information system in von Willebrand disease, inherited platelet function disorders, and rare bleeding disorders
45. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
46. Psychometrics of patient-reported outcomes measurement information system in von Willebrand disease, inherited platelet function disorders, and rare bleeding disorders
47. Desmopressin to prevent and treat bleeding in pregnant women with an inherited bleeding disorder:a systematic literature review
48. A new population pharmacokinetic model for recombinant factor IX-Fc fusion concentrate including young children with haemophilia B
49. Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants:Results from the phase III HOPE-B trial 2 years after gene therapy
50. The spectrum of neutralizing and non-neutralizing anti-FVIII antibodies in a nationwide cohort of 788 persons with hemophilia A
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.